Essa Pharma Stock Analysis

ESSA Stock Analysis Notes

About 81.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. ESSA Pharma recorded a loss per share of 0.62. The entity last dividend was issued on the 25th of April 2018. The firm had 1:20 split on the 25th of April 2018. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States. To learn more about ESSA Pharma call David MD at 778 331 0962 or check out https://www.essapharma.com.

ESSA Pharma Investment Alerts

ESSA Pharma Upcoming and Recent Events

ESSA Largest EPS Surprises

View All Earnings Estimates

ESSA Stock Institutional Investors

Note, although ESSA Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ESSA Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.23 M.

ESSA Profitablity

Management Efficiency

ESSA Pharma has return on total asset (ROA) of (0.1479) % which means that it has lost $0.1479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1983) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.86 in 2024. Return On Capital Employed is likely to drop to -1.56 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 383.8 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 181.3 K in 2024.

Technical Drivers

As of the 24th of November, ESSA Pharma shows the Standard Deviation of 10.27, market risk adjusted performance of 5.26, and Mean Deviation of 4.69. ESSA Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

ESSA Pharma Price Movement Analysis

ESSA Pharma Insider Trading Activities

ESSA Pharma Outstanding Bonds

ESSA Pharma Predictive Daily Indicators

ESSA Pharma Forecast Models

ESSA Pharma's time-series forecasting models are one of many ESSA Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ESSA Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how ESSA Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ESSA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ESSA Pharma. By using and applying ESSA Stock analysis, traders can create a robust methodology for identifying ESSA entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ESSA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ESSA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ESSA Pharma stock analysis indicators help investors evaluate how ESSA Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ESSA Pharma shares will generate the highest return on investment. By understating and applying ESSA Pharma stock analysis, traders can identify ESSA Pharma position entry and exit signals to maximize returns.

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.